Skip to main content

anti-pd-1/anti-tgfbrii bispecific antibody inca33890

Generic: Anti-PD-1/Anti-TGFbRII Bispecific Antibody INCA33890

anti-pd-1/anti-tgfbrii bispecific antibody inca33890: 4 clinical trials tracked.

anti-pd-1/anti-tgfbrii bispecific antibody inca33890 evidence translation

What we can confirm

4 tracked trials

No verified listed company relationship

What it means

AI will separate confirmed drug evidence from unknown company context.

What to watch

Watch trial status, endpoints, and the next source-backed update.
BioSniper AIPage evidence connected

Prepared research question

What is verified about anti-pd-1/anti-tgfbrii bispecific antibody inca33890, and what remains unknown?

Run cited research

Traceable citations · Unknowns marked

See linked entities and source evidence3 indications · 1 study sponsors
Clinical Trial Registry Records (4)

A Phase 2 Study of INCA33890 in the Treatment of Circulating Tumor DNA-Positive Stage II/III Microsatellite Stable Colorectal Cancer After Curative Resection and Chemotherapy (NEXERA-204)

NCT07823322Registry updated 2026-09-22·Phase 2·INCY
Not yet recruiting

Primary endpoint: Circulating tumor DNA (ctDNA) clearance

Interventionalopen40 targetStarted 2026-10Completion 2029-05Incyte Corporation

A Randomized, Double-Blind, Phase 3 Study of Standard-of-Care Chemotherapy and Bevacizumab With or Without INCA33890 in the First-Line Treatment of Metastatic Microsatellite Stable Colorectal Cancer

NCT07284849Registry updated 2026-10-09·Phase 3·INCY
Recruiting

Primary endpoint: Progression-Free Survival (PFS)

InterventionalRandomizedquadruple700 targetStarted 2026-03Completion 2029-09293 sites · Argentina, Australia, Austria, Belgium…Incyte Corporation

A Phase 1, Open-Label, Multicenter Study of INCB161734 in Participants With Advanced or Metastatic Solid Tumors With KRAS G12D Mutation

NCT06179160Registry updated 2026-07-22·Phase 1·INCY
Recruiting

Primary endpoint: Number of participants with Dose Limiting Toxicities (DLTs)

Interventionalopen710 targetStarted 2024-01Completion 2027-0134 sites · Australia, Belgium, Canada, France…Incyte Corporation

A Phase 1, Open-Label, Multicenter Study of INCA33890 in Participants With Advanced or Metastatic Solid Tumors

NCT05836324Registry updated 2026-07-23·Phase 1·INCY
Recruiting

Primary endpoint: Dose Limiting Toxicities (DLTs)

Interventionalopen570 targetStarted 2023-07Completion 2029-0539 sites · China, Denmark, France, Italy…Incyte Corporation